Case Presentation {#sec1_1}
=================

A 70-year-old Japanese man presented at our hospital with an asymptomatic, 20 × 30 mm irregularly shaped blackish, flat elevated plaque with a gray nodule in the periphery on his left lower leg (fig. [1a](#F1){ref-type="fig"}). The lesion had been present for 10 years and had recently enlarged, associated with bleeding. He had a medical history of stenocardia, aortic stenosis and cerebral infarction. Dermoscopy revealed leaf-like areas, large blue-gray ovoid nests and multiple blue-gray globules (fig. [1b](#F1){ref-type="fig"}). Basal cell carcinoma and malignant melanoma were listed as suspected diagnoses, and we performed an excisional biopsy of the tumor.

Histopathological examination of the tumor revealed infundibular structures of the outer hair sheath in the center of the plaque, which consisted of three distinct parts (fig. [2a](#F2){ref-type="fig"}). The first part showed circumscribed massive aggregation of basophilic basaloid cells containing abundant melanin granules with peripheral palisading and retraction spaces (fig. [2b](#F2){ref-type="fig"}). The second part showed aggregation of clear cells without nuclear atypia or mitosis. This part of the tumor exhibited trichilemmal keratinization with squamous eddies, which were surrounded by a fibrous stroma (fig. [2c](#F2){ref-type="fig"}). The third part showed reticular aggregation of basaloid cells with small infundibular cystic structures in the papillary dermis (fig. [2d](#F2){ref-type="fig"}). The stromal part showed no fibrosis and abundant mucin deposition staining positive with alcian blue (fig. [3a](#F3){ref-type="fig"}). Immunohistochemical staining revealed diffuse positivity for anti-bcl-2 in the first part (fig. [3b](#F3){ref-type="fig"}), positivity only at the periphery of tumor nests in the second part (fig. [3c](#F3){ref-type="fig"}), and diffuse positivity in the third part (fig. [3d](#F3){ref-type="fig"}). However, all parts of the tumor showed no staining for CK20 or BerEp4.

Discussion {#sec1_2}
==========

Microscopic examination of the tumor showed that it consisted of three distinct histological types: massive aggregation of basophilic cells was diagnosed as solid-type basal cell carcinoma, massive aggregation of clear cells with trichilemmal keratinization was diagnosed as proliferating trichilemmal tumor, and reticular small aggregations of basophilic basaloid cells in the papillary dermis were diagnosed as infundibulocystic basal cell carcinoma.

Infundibulocystic basal cell carcinoma was first described as 'basal cell carcinoma with follicular differentiation' in 1987 by Tozawa and Ackerman \[[@B1]\], and later in 1990 the tumor was proposed as a variant of basal cell carcinoma showing differentiation to infundibular cyst-like structures by Walsh and Ackerman \[[@B2]\]. Clinically, the tumor presents as small papules/nodules, most commonly on the face. Characteristic histopathological features of the tumor are small symmetrical, circumscribed aggregations of basaloid cells containing numerous infundibular cyst-like structures. One of the differential diagnoses of infundibulocystic basal cell carcinoma is trichoepithelioma. Infundibulocystic basal cell carcinoma is different from trichoepithelioma in that there are no follicular bulbs and papillae, no stromal fibrosis around the tumor, reticulated pattern of neoplastic cells, and abundant epithelial mucin \[[@B2]\]. In the present case, anti-bcl-2 immunohistochemical staining was diffusely positive in portions of typical basal cell carcinoma and infundibulocystic basal cell carcinoma. Bcl-2 is a photo-oncogene related to programmed cell death \[[@B3]\]. In normal skin, bcl-2 is present within basal keratinocytes, mesenchymal cells of follicular papilla, clear cells of eccrine glands, melanocytes and lymphocytes \[[@B3]\]. Anti-bcl-2 staining is useful for distinguishing between trichoepitheliomas and basal cell carcinoma \[[@B4]\], the former staining positively in the periphery of tumor nests, whereas the latter shows diffuse and widespread staining in all tumor nests \[[@B5]\].

Basal cell carcinoma is a neoplasm proposed to be derived from epithelial germ cells, and infundibulocystic basal cell carcinoma is derived from the infundibulum of the hair follicle \[[@B6]\], whereas proliferating trichilemmal tumor is derived from the hair follicle isthmus \[[@B7]\]. There have been four reports of basal cell carcinoma arising with trichilemmoma without a pre-existing sebaceous nevus \[[@B8]\]. Taken together, the present findings suggest that basal cell carcinoma may be derived from hair germ cells, including the outer hair sheath and hair follicular infundibulum.
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![**a** Clinical image. The tumor was asymmetric, flat and blackish-colored with a gray nodule. **b** The dermoscopic image revealed leaf-like areas, large blue-gray ovoid nests and multiple blue-gray globules.](cde-0007-0352-g01){#F1}

![**a** At low magnification, histopathological examination showed a well-circumscribed tumor consisting of three distinct parts and accompanied by a hair follicle in the center. **b** Massive aggregation of basophilic basaloid cells with peripheral palisading and retraction spaces around the tumor. **c** Massive aggregation of clear cells with squamous eddies exhibiting trichilemmal keratinization. **d** Reticular aggregation of basaloid cells with infundibular cysts in the papillary dermis.](cde-0007-0352-g02){#F2}

![**a** Alcian blue stain showed abundant mucin deposition in the stoma. **b** Massive aggregation of basophilic basaloid cells showing diffuse positive staining with anti-bcl-2 antibody. **c** Massive aggregation of clear cells staining positively only at the periphery of tumor nests with anti-bcl-2 antibody. **d** Reticular aggregation of basaloid cells showing diffuse positive staining with anti-bcl-2 antibody.](cde-0007-0352-g03){#F3}
